Investigational drug · Phase 3
HSK16149
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Central Neuropathic Pain.
Phase 3Last checked: Nov 20, 2026Latest source record: May 20, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
13
Any phase or sponsor naming "HSK16149"
First trial start
2024
May 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK16149", any sponsor or status.
Conditions studied
As listed on its trial records.
- Central Neuropathic Pain
Approved drugs for the same conditions: Neuropathic pain · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK16149" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic PainPivotal-lookingStatus unknown
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT04647773 · 687 participants (planned) · Start Dec 2, 2020 · Primary completion Nov 9, 2022
Drug: HSK16149 20mg BID; HSK16149 40mg BID and 4 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Beijing, China
- Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in ChinaPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06422117 · 408 participants (planned) · Start May 30, 2024 · Primary completion Jul 30, 2027
Drug: HSK16149 20mg-40mg BID; Placebo · For: Central Neuropathic Pain
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic NeuralgiaPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05140863 · 372 participants · Start Nov 1, 2021 · Primary completion Dec 22, 2022
Drug: HSK16149 20mg BID; HSK16149 40mg BID and 1 more · For: Postherpetic Neuralgia
Sites: Nanjing, China; Nanchang, China
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic NeuralgiaPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05763550 · 331 participants · Start Feb 27, 2023 · Primary completion Jun 22, 2023
Drug: HSK16149 20mg BID; HSK16149 40mg BID and 1 more · For: Herpetic Neuralgia
Sites: Wuhan, China
- To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral NeuralgiaPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05890053 · 301 participants · Start Feb 17, 2022 · Primary completion Jul 30, 2023
Drug: HSK16149 40mg BID · For: Peripheral Neuropathic Pain
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
- HSK16149 for Perioperative Analgesia in Orthopedic SurgeryPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06007066 · 235 participants · Start Mar 8, 2023 · Primary completion Jun 12, 2023
Drug: HSK16149 capsule; Placebo · For: Post-operative Pain
Sites: Dongguan, China; Foshan, China; Guangzhou, China · 21 sites in all
- Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety DisorderPivotal-lookingRecruiting
Anhui Medical UniversityAcademic, hospital or other
NCT07330648 · 216 participants (planned) · Start Oct 10, 2025 · Primary completion Jan 31, 2027
Drug: Crisugabalin 20mg bid; Venlafaxine-XR 75mg bid and 1 more · For: Generalized Anxiety Disorder
Sites: Hefei, China
- To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in ChinaPivotal-lookingStatus unknown
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06122012 · 136 participants (planned) · Start May 1, 2023 · Primary completion Apr 30, 2024
Drug: HSK16149 20mg BID · For: Diabetic Peripheral Neuropathic Pain
Sites: Luoyang, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06490484 · 90 participants (planned) · Start Apr 19, 2024 · Primary completion Jul 12, 2024
Drug: HSK16149 20mg BID; Pregabalin 150mg BID · For: Diabetic Peripheral Neuropathic Pain
Sites: Hangzhou, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05881811 · 47 participants · Start Mar 20, 2023 · Primary completion Apr 24, 2023
Drug: HSK16149,probenecid, cimetidine · For: PHN - Post-Herpetic Neuritis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active-Controlled, Phase 2 Trial.
Li Y, Zhang F, Liu W, et al. · Diabetes Obes Metab 2026
- Translational development of crisugabalin for neuropathic pain.
João RB, Tagore Chan JO, Araújo LM, et al. · Br J Clin Pharmacol 2026
- Efficacy and safety of HSK16149 for postoperative pain in Chinese patients after orthopedic surgery: a phase 2 randomized clinical trial.
Yang L, Ma S, Liu S, et al. · Int J Surg 2026
- Is Crisugabalin Signaling the Arrival of a Third Generation of α2δ Ligands?
Alcántara Montero A · CNS Drugs 2026
- The Efficacy and Safety of Crisugabalin (HSK16149) in Fibromyalgia Patients: Protocol for a Prospective Randomized Open Blinded-Endpoint (PROBE) Study.
Liu M, Li R, Zhou H, et al. · J Pain Res 2026
- Long-Term Safety and Efficacy of Crisugabalin for Diabetic Peripheral Neuropathic Pain: A 52-Week, Multicenter, Single-Arm Trial.
Guo X, Wang K, Zhang T, et al. · J Diabetes Res 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.